Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Celldex Announces Phase 2 Results For Barzolvolimab In Chronic Inducible Urticaria; Achieves Primary Endpoint With Significant Complete Response Rates In Both Dose Groups

Author: Benzinga Newsdesk | July 29, 2024 04:10pm

First Large, Randomized, Placebo-Controlled Study To Demonstrate Success In CIndU; Plans Phase 3 Registration Development; Webcast Today At 4:30 PM ET

Posted In: CLDX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist